Notably, tissue resident CXCR6+ T cells are highly tumor-reactive and correlate with immune infiltration and immunotherapy response, thus suggesting that CXCR6+ T cells may facilitate the rational design of T cell specific therapies (for example, immune checkpoint blockade therapy or engineered TCR-T cell therapy) for the treatment of human cancer. This evidence concerns the gene CXCR6 and cancer.